To learn more or to begin testing, contact Aegis Client Services at
1-800-533-7052

First 100K Drug-Drug Interaction Sample Study :

Objective information drives patient care.

5+

Drug-Drug Interaction (DDI) Testing was developed by Aegis to bypass gaps in care left by incomplete, subjectively reported home medication lists and medical records.

Since introducing DDI Testing to the market in January of 2016, Aegis has performed over 100,000 DDI tests and has provided objective information about potentially harmful interactions to over 700 clients.

Aegis’s Drug-Drug Interaction (DDI) Testing offers healthcare providers clinically-actionable information that empowers them to combat adverse drug effects seen in their patients. Since its introduction to the market in early 2016, DDI Testing has changed the way healthcare providers care for their patients by objectively identifying substances – medications, supplements, and foods – that the patient recently ingested and that could lead to harmful adverse effects.

With the identification of these potential interactions, the healthcare provider is able to tailor their course of treatment and optimize patient care without timely or costly “trial and error” prescribing practices.

We Tested

100K

100,000 samples

53,683 unique patients

42 states

We Found

30%

30% of all samples tested were positive for at least one drug-drug interaction.

10%

10% of all samples had at least one severe or contraindicated interaction which would require action form the healthcare provider to reduce the immediate risk of potential adverse effects.

44%

Of those samples positive for an interaction, 44% had multiple drug-drug interactions which would cause additive adverse effects.

80%

80% of patients meeting polypharmacy criteria – concurrently taking at least five medications – had at least one drug-drug interaction identified.

37%

37% of all patients tested for drug-drug interactions had at least one interaction identified by Aegis.

30%

30% of all samples tested were positive for at least one drug-drug interaction.

10%

10% of all samples had at least one severe or contraindicated interaction which would require action from the healthcare provider to reduce the immediate risk of potential adverse effects.

How are DDIs categorized?

+

DDIs are categorized as:

Contraindicated

This combination of medications generally should not be administered to the same patient.

Moderate

Action is required to reduce the risk of a severe interaction.

Severe

Assess the risk of the patient and take action as needed.

44%

Of those samples positive for an interaction, 44% had multiple drug-drug interactions which would cause additive adverse effects.

Conclusion

Polypharmacy is a significant driver of drug-drug interactions.

Patients who take multiple medications are at a high risk for a drug-drug interaction and potentially harmful adverse drug effects.

Nearly 1 in 5 patients taking at least 2 medications reported a DDI.

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0

2

3

4

5

6 +

As a patient is prescribed additional medications, their risk for a drug-drug interaction increases exponentially.

Clinically-Actionable Information

Aegis’s Drug-Drug Interaction (DDI) Testing offers healthcare providers clinically-actionable information that empowers them to combat adverse drug events seen in their patients. Since its introduction to the market in early 2016, DDI Testing has changed the way healthcare providers care for their patients by objectively identifying substances – medications, supplements, and foods – that the patient recently ingested that are known causes of DDIs and put patients at increased risk for adverse drug events.

With the identification of these potential interactions and delivery of clinically-actionable information provided by Aegis, the healthcare provider is able to tailor their course of treatment and optimize patient care without timely or costly “trial and error” prescribing practices.

Learn more about DDI Testing

Keep up with the latest...

Live Webinar

First 100K DDI Samples Study Findings

Date: September 14, 2017
Time: TBD

Presented by:
Amber Watson, Pharm. D.

Sign Up

On DEMAND WEBINAR

Would patient care be improved by the ability to objectively identify pertinent drug interactions?

Presented by:
Josh Schrecker, Pharm. D.

View Playback

DDI Testing at Aegis was developed to help healthcare providers deliver exceptional patient care when prescribing – and treating patients who are prescribed by other healthcare providers – common pain management and behavioral health medications.

To learn more or to begin testing, contact Aegis Client Services at

1-800-533-7052

Ready to begin testing?

Contact Aegis Client Services at: